Clinical trials: Disorder of Circulatory System
Multiple Myeloma
CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
The purpose of this study is to see if the investigator can help the immune system to work against myeloma. This study will see if a vaccine made with altered dendritic cells will make T cells work against tumor cells.
- Trial name
- NCT01995708
- Testing
- CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs), Standard of care
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma
This clinical trial is for subjects with multiple myeloma that has returned after treatment (relapsed) or did not respond to prior treatment (refractory). The study is in two parts, Phase I and Phase II.
- Trial name
- Romi Poma (NCT01979276)
- Testing
- Romidepsin, pomalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Relapsed/Refractory Multiple Myeloma
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
Study of Plitidepsin in combination with dexamethasone versus dexamethasone alone in patients with relapsed/refractory multiple myeloma.
- Trial name
- ADMYRE (NCT01102426)
- Testing
- Plitidepsin, Dexamethasone
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 255 people
- Sponsor
- PharmaMar
Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
This randomized phase II trial studies how well celecoxib works in preventing multiple myeloma in patients with monoclonal gammopathy or smoldering myeloma.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Smoldering Multiple Myeloma
- Trial name
- NCT00099047
- Testing
- celecoxib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Diabetic Macular Edema
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLIMMER (NCT04603937)
- Testing
- KSI-301, Aflibercept
- Where
- 72 sites in United States, Czechia and 6 more
- Volunteers
- 459 people
- Sponsor
- Kodiak Sciences Inc
Venous Thromboembolism
Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System
Long-term anticoagulation is indicated in patients for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or mechanical cardiac valve replacement, prevention or treatment…
- Trial name
- vMetrics-AMS (NCT00978445)
- Testing
- vMetrics protocol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- ZIN Technologies, Inc.
Myeloma-Multiple, Myeloma, Plasma-Cell
T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma
Background: Multiple myeloma is a cancer of the blood plasma cells. It usually becomes resistant to standard treatments. Researchers have developed a procedure called gene therapy.
- Trial name
- NCT03602612
- Testing
- Cyclophosphamide, Fludarabine, Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Stroke, Stroke, Acute
A Multisite Exploration of Balance Perturbations With and Without Body Weight Support
ZeroG is an FDA-listed robotic body weight support system (BWSS). Mounted on an overhead track, patients are fitted in a harness system tethered to said track, and are able to practice gait and balance activities without the risk…
- Conditions
- Stroke, Stroke, Acute, Balance; Distorted, Balance; Impairment
- Trial name
- NCT05110300
- Testing
- Body weight support system control group, Body weight support system with balance perturbations
- Where
- 4 sites in United States
- Volunteers
- 114 people
- Sponsor
- Gaylord Hospital, Inc
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
This randomized phase II trial compares how well two different doses of carfilzomib work when given with dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement or has not…
- Trial name
- NCT01903811
- Testing
- Carfilzomib, Dexamethasone, Laboratory Biomarker Analysis
- Where
- 485 sites in United States
- Volunteers
- 143 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma
Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)
This study is designed to compare progression-free survival (PFS) from randomization among patients randomized on the BMT CTN 1302 protocol, "Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib…
- Trial name
- NCT02440464
- Testing
- Allogeneic HSCT, Fludarabine, Melphalan
- Where
- 15 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Multiple Myeloma
Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin
This study will be available to any participant who has received or is currently receiving belantamab mafodotin treatment through either a clinical trial, an access program, or a physician prescription.
- Trial name
- NCT04549363
- Testing
- Belantamab mafodotin
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Hepatitis C, Vasculitis
Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
The purpose of this study is to assess the efficacy of Rituximab (anti-CD20) in the treatment of patients with hepatitis C associated cryoglobulinemic vasculitis (HCV-CV) who have failed or are intolerant to…
- Trial name
- NCT00029107
- Testing
- Rituximab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Waldenstrom's Macroglobulinemia
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
The purpose of this research study is to assess the overall response rate of LBH589 in patients with relapsed or refractory Waldenstrom's Macroglobulinemia.
- Trial name
- NCT00936611
- Testing
- LBH589
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Dana-Farber Cancer Institute
Coronary Artery Disease
ARISTOCRAT-A Randomized Controlled Trial Evaluating Closure Following Access With the AXERA (Device Name) 2 Access System
The goal of the research study is to observe the clinical safety, effectiveness and patient satisfaction of the AXERA 2 Access System in subjects undergoing coronary angiographic and possible Percutaneous Coronary Intervention…
- Trial name
- ARISTOCRAT (NCT02061696)
- Testing
- Vascular Access Device, Standard Manual Compression
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Frank Saltiel
Hematologic Malignancies, Relapse
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
The investigators hypothesize that adding carfilzomib to standard conditioning regimen for allo-HCT for advanced or high-risk hematologic malignancies will decrease post-transplant relapse and treatment-related mortality by…
- Conditions
- Hematologic Malignancies, Relapse, Graft-Versus-Host Disease
- Trial name
- NCT02145403
- Testing
- Carfilzomib, Tacrolimus
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Michigan Rogel Cancer Center
Persistent Atrial Fibrillation
Feasibility Study of the FARAPULSE™ Cardiac Ablation System Plus in the Treatment of Persistent Atrial Fibrillation(PersAFOne II)
The objective of this safety and feasibility study is to assess whether the endocardial creation of electrically nonconductive lesions via PEF catheter ablation applied using the FARAPULSE Cardiac Ablation System Plus is a…
- Trial name
- PersAFOne II (NCT05152966)
- Testing
- Ablation
- Where
- Czechia
- Volunteers
- 20 people
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation, Stroke
DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation
This study will be conducted in male and female subjects aged 18 to 80 years, inclusive, with non-valvular AF and a CHADS2 Score of at least 1. Subjects will be treated on an outpatient basis.
- Trial name
- NCT00806624
- Testing
- DU-176b tablets, Warfarin tablets
- Where
- 4 sites in China, Singapore and 2 more
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Intracranial Aneurysm
Coil Assisted Flow Diversion Safety and Performance Study
Cerus Endovascular is sponsoring a prospective, single arm, multi-center study to document the safety and performance of Neqstent in adjunctive therapy.
- Trial name
- CAFI (NCT04187573)
- Testing
- Neqstent
- Where
- 7 sites in Austria, Canada and 3 more
- Volunteers
- 38 people
- Sponsor
- Cerus Endovascular, Inc.
Obesity
BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus
The purpose of this study is to assess the weight loss effect of lorcaserin during and at the end of 1 year of treatment in overweight and obese patients with Type II diabetes mellitus treated with metformin, sulfonylurea (SFU)…
- Trial name
- NCT00603291
- Testing
- Lorcaserin 10 mg once daily (QD), Lorcaserin 10 mg twice a day (BID)
- Where
- United States
- Volunteers
- 604 people
- Sponsor
- Eisai Inc.
Orthostatic Hypotension, Spinal Cord Injury
Safety and Efficacy of L-NAME and Midodrine to Increase MAP
After a spinal cord injury the brain is no longer completely in control of the body below the level of injury. This affects many organs and systems in the body, we are interested in understanding how a spinal cord injury affects…
- Trial name
- NCT00835224
- Testing
- L-NAME, Midodrine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- US Department of Veterans Affairs
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.